- Home
- ESE vs DNTH Comparison
ESE vs DNTH Comparison
Compare ESE & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESE | DNTH |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 5.9B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ESE | DNTH |
|---|---|---|
| Price | $249.32 | $72.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 17 |
| Target Price | ★ $352.75 | $140.80 |
| AVG Volume (30 Days) | 227.2K | ★ 895.5K |
| Earning Date | 11-19-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.13% | N/A |
| EPS Growth | ★ 193.15 | N/A |
| EPS | ★ 3.71 | N/A |
| Revenue | ★ $37,000,000.00 | $2,036,000.00 |
| Revenue This Year | $19.87 | N/A |
| Revenue Next Year | $18.41 | N/A |
| P/E Ratio | $67.98 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $193.68 | $32.28 |
| 52 Week High | $362.15 | $117.88 |
Technical Indicators
Market Signals| Indicator | ESE | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 33.86 | 15.05 |
| Support Level | N/A | $68.85 |
| Resistance Level | $275.92 | $91.36 |
| Average True Range (ATR) | 7.11 | 3.78 |
| MACD | -0.53 | -0.93 |
| Stochastic Oscillator | 11.04 | 14.37 |
Price Performance
Historical ComparisonAbout ESE ESCO Technologies Inc.
ESCO Technologies Inc sells engineered products and systems for utility, industrial, aerospace, and commercial applications. The firm operates in three segments: Aerospace & Defense (A&D), Utility Solutions Group (USG), and RF Test & Measurement (Test). The Aerospace and Defense segment designs and manufactures specialty filtration and naval products. The USG segment provides diagnostic testing solutions. The Test segment provides its customers with the ability to identify, measure, and contain magnetic, electromagnetic, and acoustic energy.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.